HOME  | CONTACT  | PATIENT LOGIN  | CLINIC LOGIN  | FAQ
  • PATIENTS &
    HEALTHY VOLUNTEERS
  • INVESTIGATORS
  • CROS / SPONSORS
  • CAREERS
  • TRIAL ALERTS

TRIALS SEARCH
      
  • HEALTH NEWS

  • RSS FEEDS

  • ABOUT TRIALS

  • LINK TO US


View Clinical Trial (Medical Research Study)


A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma

Signup
Browse Studies

City:   Iowa City
State:   Iowa
Zip Code:   52240
Conditions:   Asthma
Purpose:   Study CQMF149A2210 will evaluate the safety of QMF149 Twisthaler® 500/400 μg, a fixed dose combination of indacaterol 500 μg, a once daily β2 agonist, and mometasone furoate 400 μg, an inhaled corticosteroid that is approved for use in the treatment of asthma. The objective of this safety trial is to asses the effect of treatment on the incidence of serious asthma exacerbations, defined as asthma related hospitalization and/or intubation and/or death. This is an event driven trial.
Study Summary:  
Criteria:   Inclusion Criteria: - Patients with a documented diagnosis of persistent asthma and who are currently treated with or qualify for treatment with both ICS and LABA combination - Patients demonstrating an increase in FEV1 of ≥ 12% or ≥ 200 mLs within 30 minutes after administration of β2-agonist (SABA) - Patients with an FEV1 ≥ 50% of predicted normal Exclusion Criteria: - Patients with a previous diagnosis of COPD - Patients who have had an asthma attack/exacerbation requiring hospitalization/emergency room visit or respiratory tract infection within 1 month prior to randomization - Patients who have ever required ventilator support for respiratory failure - Patients with diabetes Type I or uncontrolled diabetes Type II - Patients with concomitant pulmonary disease - Patients with certain cardiovascular co-morbid conditions - Patients with any significant medical condition that might compromise patient safety, interfere with evaluation or preclude completion of the study Other protocol-defined inclusion/exclusion criteria may apply
NCT ID:   NCT00941798
Primary Contact:   Study Director
Novartis Pharmaceuticals
Novartis Pharmaceuticals

Novartis Pharmaceuticals
Phone: 862-778-8300
Backup Contact:   N/A
Location Contact:   Iowa City, Iowa 52240
United States



There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:   ClinicalTrials.gov
Date Processed:   May 19, 2013
Modifications to this listing:   Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


  • NEARBY STUDIES

 
Clinical Connections Home | Investigators | CROs / Sponsors | Clinical Trials Notification | Search Clinical Trials | About Clinical Trials | Links | Terms And Conditions | Sitemap | Suggestions / Feedback
© 1998-2013 | All trademarks are property of their legal owners. | All Rights Reserved

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted worldwide.

ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.